This is a retrospective study that included 60 cancer patients who underwent autologous NK cell and CD8 T cell therapy between January 2016 and December 2021
The dysfunction and reduced proliferation of peripheral immune cells including CD8 T and NK cells have been observed in both aging and cancer patients, thereby challenging the immune cell therapy in these subjects. Therefore, we evaluated the growth of these lymphocytes in elderly patients with several types of cancer and the correlation of peripheral blood (PB) indexes to the expansions. This is a retrospective study that included 60 cancer patients who underwent autologous NK cell and CD8 T cell therapy between January 2016 and December 2021. By optimizing the antiviral and tumor surveillance ability of both NK cells and CTLs through serial steps from isolation and expansion, followed by re-infusion of these activated cells back to the patient body, AIET has become a promising, cutting-edge method in detecting and eliminating cancer cells. The study aimed to evaluate the safety and effectiveness of 60 cancer patientsreceiving AIET.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Autologous NK cell and CD8 T cell therapy for cancer patients
Vinmec Research Institute of Stem Cell and Gene Technology
Hanoi, Vietnam
Number of Adverse events and serious adverse events (AEs or SAEs)
the number of AEs or SAEs during and after Autologous Immune Enhancement Therapy (AIET)
Time frame: up to the 36-month period following treatment
Changes in health-related quality of life of patients
Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0
Time frame: up to the 36-month period following treatment
Survival time of patients in this study
Survival time was defined as from the date of diagnosis until death or the end of this study
Time frame: up to the 36-month period following treatment
Changes in Symptoms of patients using MD Anderson Symptoms Inventory Gastrointestinal Cancer Module (MDASI )
MDASI contains a 24-item questionnaire. MDASI-GI symptom items are assessed on a numeric scale ranging from 0 or "not present" to 10 or "as bad as you can imagine". The MDASI is a concise, internally stable, and sensitive tool for measuring multiple-symptom severity and symptom interference with function in patients with cancer.
Time frame: up to the 36-month period following treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.